Cargando…

An Antivector Vaccine Protects against a Lethal Vector-Borne Pathogen

Vaccines that target blood-feeding disease vectors, such as mosquitoes and ticks, have the potential to protect against the many diseases caused by vector-borne pathogens. We tested the ability of an anti-tick vaccine derived from a tick cement protein (64TRP) of Rhipicephalus appendiculatus to prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Labuda, Milan, Trimnell, Adama R, Ličková, Martina, Kazimírová, Mária, Davies, Gillian M, Lissina, Olga, Hails, Rosie S, Nuttall, Patricia A
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1424664/
https://www.ncbi.nlm.nih.gov/pubmed/16604154
http://dx.doi.org/10.1371/journal.ppat.0020027
_version_ 1782127186143084544
author Labuda, Milan
Trimnell, Adama R
Ličková, Martina
Kazimírová, Mária
Davies, Gillian M
Lissina, Olga
Hails, Rosie S
Nuttall, Patricia A
author_facet Labuda, Milan
Trimnell, Adama R
Ličková, Martina
Kazimírová, Mária
Davies, Gillian M
Lissina, Olga
Hails, Rosie S
Nuttall, Patricia A
author_sort Labuda, Milan
collection PubMed
description Vaccines that target blood-feeding disease vectors, such as mosquitoes and ticks, have the potential to protect against the many diseases caused by vector-borne pathogens. We tested the ability of an anti-tick vaccine derived from a tick cement protein (64TRP) of Rhipicephalus appendiculatus to protect mice against tick-borne encephalitis virus (TBEV) transmitted by infected Ixodes ricinus ticks. The vaccine has a “dual action” in immunized animals: when infested with ticks, the inflammatory and immune responses first disrupt the skin feeding site, resulting in impaired blood feeding, and then specific anti-64TRP antibodies cross-react with midgut antigenic epitopes, causing rupture of the tick midgut and death of engorged ticks. Three parameters were measured: “transmission,” number of uninfected nymphal ticks that became infected when cofeeding with an infected adult female tick; “support,” number of mice supporting virus transmission from the infected tick to cofeeding uninfected nymphs; and “survival,” number of mice that survived infection by tick bite and subsequent challenge by intraperitoneal inoculation of a lethal dose of TBEV. We show that one dose of the 64TRP vaccine protects mice against lethal challenge by infected ticks; control animals developed a fatal viral encephalitis. The protective effect of the 64TRP vaccine was comparable to that of a single dose of a commercial TBEV vaccine, while the transmission-blocking effect of 64TRP was better than that of the antiviral vaccine in reducing the number of animals supporting virus transmission. By contrast, the commercial antitick vaccine (TickGARD) that targets only the tick's midgut showed transmission-blocking activity but was not protective. The 64TRP vaccine demonstrates the potential to control vector-borne disease by interfering with pathogen transmission, apparently by mediating a local cutaneous inflammatory immune response at the tick-feeding site.
format Text
id pubmed-1424664
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-14246642006-05-01 An Antivector Vaccine Protects against a Lethal Vector-Borne Pathogen Labuda, Milan Trimnell, Adama R Ličková, Martina Kazimírová, Mária Davies, Gillian M Lissina, Olga Hails, Rosie S Nuttall, Patricia A PLoS Pathog Research Article Vaccines that target blood-feeding disease vectors, such as mosquitoes and ticks, have the potential to protect against the many diseases caused by vector-borne pathogens. We tested the ability of an anti-tick vaccine derived from a tick cement protein (64TRP) of Rhipicephalus appendiculatus to protect mice against tick-borne encephalitis virus (TBEV) transmitted by infected Ixodes ricinus ticks. The vaccine has a “dual action” in immunized animals: when infested with ticks, the inflammatory and immune responses first disrupt the skin feeding site, resulting in impaired blood feeding, and then specific anti-64TRP antibodies cross-react with midgut antigenic epitopes, causing rupture of the tick midgut and death of engorged ticks. Three parameters were measured: “transmission,” number of uninfected nymphal ticks that became infected when cofeeding with an infected adult female tick; “support,” number of mice supporting virus transmission from the infected tick to cofeeding uninfected nymphs; and “survival,” number of mice that survived infection by tick bite and subsequent challenge by intraperitoneal inoculation of a lethal dose of TBEV. We show that one dose of the 64TRP vaccine protects mice against lethal challenge by infected ticks; control animals developed a fatal viral encephalitis. The protective effect of the 64TRP vaccine was comparable to that of a single dose of a commercial TBEV vaccine, while the transmission-blocking effect of 64TRP was better than that of the antiviral vaccine in reducing the number of animals supporting virus transmission. By contrast, the commercial antitick vaccine (TickGARD) that targets only the tick's midgut showed transmission-blocking activity but was not protective. The 64TRP vaccine demonstrates the potential to control vector-borne disease by interfering with pathogen transmission, apparently by mediating a local cutaneous inflammatory immune response at the tick-feeding site. Public Library of Science 2006-04 2006-04-07 /pmc/articles/PMC1424664/ /pubmed/16604154 http://dx.doi.org/10.1371/journal.ppat.0020027 Text en © 2006 Labuda et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Labuda, Milan
Trimnell, Adama R
Ličková, Martina
Kazimírová, Mária
Davies, Gillian M
Lissina, Olga
Hails, Rosie S
Nuttall, Patricia A
An Antivector Vaccine Protects against a Lethal Vector-Borne Pathogen
title An Antivector Vaccine Protects against a Lethal Vector-Borne Pathogen
title_full An Antivector Vaccine Protects against a Lethal Vector-Borne Pathogen
title_fullStr An Antivector Vaccine Protects against a Lethal Vector-Borne Pathogen
title_full_unstemmed An Antivector Vaccine Protects against a Lethal Vector-Borne Pathogen
title_short An Antivector Vaccine Protects against a Lethal Vector-Borne Pathogen
title_sort antivector vaccine protects against a lethal vector-borne pathogen
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1424664/
https://www.ncbi.nlm.nih.gov/pubmed/16604154
http://dx.doi.org/10.1371/journal.ppat.0020027
work_keys_str_mv AT labudamilan anantivectorvaccineprotectsagainstalethalvectorbornepathogen
AT trimnelladamar anantivectorvaccineprotectsagainstalethalvectorbornepathogen
AT lickovamartina anantivectorvaccineprotectsagainstalethalvectorbornepathogen
AT kazimirovamaria anantivectorvaccineprotectsagainstalethalvectorbornepathogen
AT daviesgillianm anantivectorvaccineprotectsagainstalethalvectorbornepathogen
AT lissinaolga anantivectorvaccineprotectsagainstalethalvectorbornepathogen
AT hailsrosies anantivectorvaccineprotectsagainstalethalvectorbornepathogen
AT nuttallpatriciaa anantivectorvaccineprotectsagainstalethalvectorbornepathogen
AT labudamilan antivectorvaccineprotectsagainstalethalvectorbornepathogen
AT trimnelladamar antivectorvaccineprotectsagainstalethalvectorbornepathogen
AT lickovamartina antivectorvaccineprotectsagainstalethalvectorbornepathogen
AT kazimirovamaria antivectorvaccineprotectsagainstalethalvectorbornepathogen
AT daviesgillianm antivectorvaccineprotectsagainstalethalvectorbornepathogen
AT lissinaolga antivectorvaccineprotectsagainstalethalvectorbornepathogen
AT hailsrosies antivectorvaccineprotectsagainstalethalvectorbornepathogen
AT nuttallpatriciaa antivectorvaccineprotectsagainstalethalvectorbornepathogen